Carboplatin-based combination chemotherapy for elderly patients with advanced bladder cancer

Yoneyama, Takahiro; Tobisawa, Yuki; Yoneyama, T.; Yamamoto, Hayato; Imai, Atsushi; Hatakeyama, Shingo; Hashimoto, Yasuhiro; Koie, Takuya; Οhyama, Chikara

doi:10.1007/s10147-014-0706-2

Cited by 15 publications

(8 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All urothelial cancer patients underwent chemotherapy at hospitalization. Most patients received either gemcitabine 800 to 1000 mg/m 2 on days 1, 8, and 15 plus cisplatin 70 mg/m 2 (GCis) on day 2 every 3 weeks, or gemcitabine 800 to 1000 mg/m 2 on days 1, 8, and 15 plus carboplatin (GCarbo) at an area under the curve of 4 to 4.5 according to the Calvert formula on day 2 every 3 weeks, for 2–4 cycles [ 19 , 27 ]. Only a few patients underwent standard dose of MVAC (methotrexate: 30 mg/m 2 , days 1, 15, 22; vinblastine: 3 mg/m 2 , days 2, 15, 22; doxorubicin: 30 mg/m 2 , day 2; and cisplatin: 70 mg/m 2 , day 2) or docetaxel-based regimen (docetaxel: 75 mg/m 2 , day 1; ifosfamide: 2.0 g/m 2 , days 1–3 and nedaplatin: 75 mg/m 2 , day 2).…”

Section: Methodsmentioning

confidence: 99%

Oncological outcomes of neoadjuvant chemotherapy in patients with locally advanced upper tract urothelial carcinoma: a multicenter study

et al. 2017

Self Cite

View full text Add to dashboard Cite

ObjectiveThe clinical impact of neoadjuvant chemotherapy (NAC) on oncological outcomes in patients with locally advanced upper tract urothelial carcinoma (UTUC) remains unclear. We investigated the oncological outcomes of platinum-based NAC for locally advanced UTUC.ResultsOf 234 patients, 101 received NAC (NAC group) and 133 did not (Control [Ctrl] group). The regimens in the NAC group included gemcitabine and carboplatin (75%), and gemcitabine and cisplatin (21%). Pathological downstagings of the primary tumor and lymphovascular invasion were significantly improved in the NAC than in the Ctrl groups. NAC for locally advanced UTUC significantly prolonged recurrence-free and cancer-specific survival. Multivariate Cox regression analysis using an inverse probability of treatment weighted (IPTW) method showed that NAC was selected as an independent predictor for prolonged recurrence-free and cancer-specific survival. However, the influence of NAC on overall survival was not statistically significant.Materials and MethodsA total of 426 patients who underwent radical nephroureterectomy at five medical centers between January 1995 and April 2017 were examined retrospectively. Of the 426 patients, 234 were treated for a high-risk disease (stages cT3–4 or locally advanced [cN+] disease) with or without NAC. NAC regimens were selected based on eligibility of cisplatin. We retrospectively evaluated post-therapy pathological downstaging, lymphovascular invasion, and prognosis stratified by NAC use. Multivariate Cox regression analysis was performed for independent factors for prognosis.ConclusionsPlatinum-based NAC for locally advanced UTUC potentially improves oncological outcomes. Further prospective studies are needed to clarify the clinical benefit of NAC for locally advanced UTUC.

show abstract

Section: Methodsmentioning

confidence: 99%

Oncological outcomes of neoadjuvant chemotherapy in patients with locally advanced upper tract urothelial carcinoma: a multicenter study

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…All patients underwent chemotherapy in the hospital. Patients received either gemcitabine 800–1000 mg/m 2 on days 1, 8, and 15 plus cisplatin 70 mg/m 2 on day 2 every 3 weeks or gemcitabine 800–1000 mg/m 2 on days 1, 8, and 15 plus carboplatin at an area under the curve of 4–4.5 according to the Calvert formula on day 2 every 3 weeks, for 2 to 4 cycles [ 16 , 18 ]. Tumor response was evaluated after the second course of NAC.…”

Section: Methodsmentioning

confidence: 99%

Trends in neoadjuvant chemotherapy use and oncological outcomes for muscle-invasive bladder cancer in Japan: a multicenter study

et al. 2017

Self Cite

View full text Add to dashboard Cite

ObjectiveDespite benefits of neoadjuvant chemotherapy (NAC), the adoption of guideline recommendations for NAC use in patients with muscle-invasive bladder cancer (MIBC) has been slow. We aimed to evaluate temporal trends in NAC use and oncological outcomes in a representative cohort of patients with MIBC.MethodsWe included 532 patients from 4 hospitals who underwent radical cystectomy (RC) for ≥ cT2 MIBC in 1996–2017. We retrospectively evaluated temporal changes in NAC use and progression-free and overall survival. Candidates for NAC were administered with either cisplatin- or carboplatin-based regimens. The impact of NAC on oncological outcomes was examined using multivariate Cox regression analysis with inverse probability of treatment weighting (IPTW) models.ResultsOf 532 patients, 336 underwent NAC followed by RC (NAC group) and 196 underwent RC alone (Ctrl group). NAC use significantly increased from 10% (1996–2004) to 83% (2005–2016). The number of patients administered with cisplatin- and carboplatin-based regimens was 43 and 280, respectively. Oncological outcomes in the NAC group were significantly improved compared to those in the Ctrl group. Multivariable analysis with IPTW models revealed that NAC significantly improved oncological outcomes in patients with MIBC. A nomogram for 5-year overall survival predicted 16% improvement in patients undergoing NAC.ConclusionsNAC use for MIBC increased after 2005. Platinum-based NAC for MIBC potentially improves oncological outcomes.

show abstract

“…All urothelial cancer patients received chemotherapy on hospitalization. Patients received either 800 mg/m 2 gemcitabine on days 1, 8 and 15 plus 70 mg/m 2 GCis on day 2 every 3 weeks, or 800 mg/m 2 gemcitabine on days 1, 8 and 15 plus GCb at an area under the curve of four according to the Calvert formula on day 2 every 3 weeks for two cycles …”

Section: Methodsmentioning

confidence: 99%

Difference in toxicity reporting between patients and clinicians during systemic chemotherapy in patients with urothelial carcinoma

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

Carboplatin-based combination chemotherapy for elderly patients with advanced bladder cancer

Abstract: Our study demonstrates that GCarbo is a safe and effective combination chemotherapy in elderly patients with advanced bladder cancer. However, the GCarboD regimen appears to have limited effectiveness for nonresponders to GCarbo therapy.

Cited by 15 publications

References 16 publications

Oncological outcomes of neoadjuvant chemotherapy in patients with locally advanced upper tract urothelial carcinoma: a multicenter study

Oncological outcomes of neoadjuvant chemotherapy in patients with locally advanced upper tract urothelial carcinoma: a multicenter study

Trends in neoadjuvant chemotherapy use and oncological outcomes for muscle-invasive bladder cancer in Japan: a multicenter study

Difference in toxicity reporting between patients and clinicians during systemic chemotherapy in patients with urothelial carcinoma

Contact Info

Product

Resources

About